Navigation Links
FDA Accepts NDA Filing for Retigabine
Date:12/30/2009

ALISO VIEJO, Calif., Dec. 30 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for the investigational drug retigabine, a neuronal potassium channel opener for the adjunctive treatment for adult epilepsy patients with partial-onset seizures. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA was successfully validated thus enabling the MAA review to commence. The filings were submitted on October 30, 2009.

About Retigabine

Retigabine is a neuronal potassium channel opener currently in late-stage development as an adjunctive treatment for adult patients with partial-onset seizures. In Phase III epilepsy trials, retigabine reduced seizure rates compared to patients taking placebo. The most common adverse reactions (incidence greater than or equal to 5% and twice placebo) across all completed trials to date are dizziness, fatigue, confusional state, vertigo, tremor, coordination abnormal, diplopia (double vision), disturbance in attention, asthenia (weakness), and visual blurring.

Retigabine Important Note

As an investigational drug, retigabine has not been found by the Food and Drug Administration (FDA) or any other regulatory agency to be safe or effective in the treatment of any disease or illness. It may not be commercialized in the United States unless and until the FDA has approved a NDA. Similar restrictions apply in other countries.

Collaboration Agreement with GlaxoSmithKline

Valeant has a worldwide License and Collaboration Agreement with GlaxoSmithKline (NYSE: GSK), to develop and commercialize retigabine. Valeant will collaborate with GSK on the development and marketing of retigabine in the United States, Australia, New Zealand, Canada and Puerto Rico (Collaboration Territory) and GSK has an exclusive license to develop and commercialize retigabine in countries outside of the Collaboration Territory and certain backup compounds to retigabine worldwide.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)



    Contact:
    Laurie W. Little
    Valeant Pharmaceuticals
    949-461-6002
    laurie.little@valeant.com


SOURCE Valeant Pharmaceuticals International


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Center to Advance Palliative Care Director and MacArthur Recipient, Diane E. Meier, MD, Accepts Fellowship Post With Senate HELP Committee
2. Freudenberg-NOK CEO Accepts New Position
3. AstraZeneca Accepts Secretary of Defense Award for Supporting Employees Serving in National Guard and Reserve
4. FDA Accepts to File Cell Therapeutics New Drug Application for Pixantrone
5. FDA Accepts Drug Application for Miconazole Lauriad(R) to Treat Oropharyngeal Candidiasis
6. Erik Estrada Accepts Honorary Appointment from Project Lifesaver International
7. House Energy & Commerce Committee Accepts Independence at Home Pilot Program as Amendment During Health Bill Markup
8. FDA Accepts Tris Pharmas ANDA with Paragraph IV Certification for a Generic Equivalent to Delsym
9. Victory Pharma, Inc. Announces FDA Accepts MGX006 NDA for Review
10. Specialty Hospitals of America Accepts First Patients in New Long Term Critical Care Hospital Located in South East Washington
11. FDA Accepts Final Section of NDA Filing for LUCASSIN(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Linda, Ca (PRWEB) , ... January 19, 2017 ... ... virtual events for tech innovators, engineers, and scientists from around the world, announces ... site offers users a quick and easy portal to research breakthroughs and trending ...
(Date:1/19/2017)... Utah (PRWEB) , ... January 19, 2017 , ... ... Festival in a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew Petersen and ... provide a condensed version of the clinic’s leading recovery program. , “We ...
(Date:1/19/2017)... ... 2017 , ... Bio-Optronics Inc. is proud to announce the ... to seamlessly integrate and streamline the way researchers prepare and conduct patient visits. ... and improving efficiency significantly for users – a first in the CTMS industry. ...
(Date:1/19/2017)... ... 19, 2017 , ... Workrite Ergonomics announced this week the ... privacy panel system was designed to deliver the ideal blend of acoustic and ... provide the visual privacy required to maintain concentration levels and increase productivity. The ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady Insurance Agency, ... communities throughout eastern Georgia, is embarking on a charity effort to raise awareness ... more Americans every year than anything else, yet risk factors associated with heart ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017 The Global Therapy Partnering ... access to partnering deals and agreements entered into by ... partnering deals - Top deals by value - Deals ... technology type The report provides understanding and access ... the world,s leading healthcare companies. The report provides ...
(Date:1/19/2017)... 2017 Report Details ... Alzheimer,s Disease Therapeutics ... – our new study reveals trends, R&D progress, and ... affecting the Alzheimer,s disease therapeutics and diagnostics market. Our ... questions: - How is the Alzheimer,s disease therapeutics and ...
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ( ... treat mitochondrial dysfunction, today announced new additions to its ... as Chief Medical Officer, and Daniel Geffken ... that Jim Carr , Pharm.D. has been promoted ... are pleased to welcome Doug and Daniel to our ...
Breaking Medicine Technology: